Israël - Engels - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg/vial - decitabine - decitabine s.k. is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. decitabine s.k. is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

Malta - Engels - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Malta - Engels - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Malta - Engels - Medicines Authority

onkovis gmbh grube 45, 82377 penzberg , germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Malta - Engels - Medicines Authority

onkovis gmbh grube 45, 82377 penzberg , germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Ierland - Engels - HPRA (Health Products Regulatory Authority)

ever valinject gmbh - azacitidine - powder for suspension for injection - 25 milligram(s)/millilitre - azacitidine

Singapore - Engels - HSA (Health Sciences Authority)

advagen pte. ltd. - azacitidine - injection, powder, for suspension - azacitidine 100mg/vial

Europese Unie - Engels - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidine - leukemia, myeloid, acute - antineoplastic agents - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Ierland - Engels - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - azacitidine - powder for suspension for injection - 25 milligram(s)/millilitre - azacitidine

Jordanië - Engels - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الشرق شخشير - orient drug store co - decitabine 50 milligram - 50 milligram